Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Pharmacolog's Year-end Bulletin 2022

Press release: Uppsala, February 17, 2023. Pharmacolog i Uppsala AB (publ) Year-end Bulletin 2022 is now available on the company’s website (Swedish only).Fjärde kvartalet 1 oktober – 31 december 2022 · Koncernens nettoomsättning för det fjärde kvartalet uppgick till 1 785 (3 838) KSEK. · Koncernens orderingång för det fjärde kvartalet uppgick till 4 350 (2 647) KSEK. · Rörelseresultatet för kvartalet uppgick till -6 763 (-2 976) KSEK. · Nettoresultat per aktie före och efter utspädning var för kvartalet -0,36 (-0,20) SEK. Perioden 1 januari – 31 december 2022 ·

Year-end report January – December 2022

OSLO, NORWAY, 17 February 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 January – December 31, 2022. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“Interest in and awareness of microbiome diagnostics are continuously increasing, which we have seen great examples of during 2022. The FDA approval of the microbiome-altering drug by Ferring affiliate Rebiotix Inc was a major milestone for the

Implantica publishes Year-end Report, January – December 2022 (Q4)

Implantica publishes Year-end Report, January – December 2022 (Q4)Significant events in the fourth quarter of 2022 · Spire Manchester Hospital is now performing RefluxStop™ procedures. Spire Manchester is part of Spire Healthcare Group, a network of 39 hospitals and 8 clinics across England, Wales and Scotland. · Implantica receives Global Health & Pharma’s Award; Most Innovative MedTech Company– Central Europe for 2022 based on a serious due diligence by GHP, identifying the high innovation level of Implantica. · Implantica attended the European Foregut Society (EFS) Conference

Optomed Plc: Financial statements bulletin, January – December 2022

Optomed Plc         Stock Exchange Release    17 February 2023 at 9:00, Helsinki Optomed Plc: Financial statements bulletin, January-December 2022 October – December 2022 · Revenue increased by 13.0 percent to EUR 4.0 (3.6) million. · Devices segment revenue decreased by 4.0 percent to EUR 1.3 (1.3) million. · Software segment revenue increased by 23.2 percent to EUR 2.7 (2.2) million driven by strong healthcare solution sales. · EBITDA amounted to EUR -0.3 (-1.5) million corresponding to -8.7 (-43.0) percent of revenue. · Optomed successfully completed directed share

Stora Enso contributes to a sustainable FIS Nordic World Ski Championships in Planica

STORA ENSO OYJ PRESS RELEASE 17 February 2023 at 9:00 EETAs the presenting sponsor of the FIS Nordic World Ski Championships in Planica, Slovenia taking place between 21 February and 5 March 2023, Stora Enso will provide wood-based renewable and recyclable products and innovations to contribute to a world-class sustainable and climate-friendly event.“The ski championships in Planica will reach a total audience of around 450 million people, enabling the opportunity to promote Stora Enso’s renewable materials while demonstrating that people can make real carbon reductions in their everyday

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseFebruary 17, 2023, at 9.00 am EETRepurchase of Outokumpu’s own shares On February 16, 2023, Outokumpu has completed repurchases its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |18,171 |5.4698

Spectacular element façades give New Babylon an iconic look

New Babylon includes the renovation and extension of the former Babylon building, designed by J.A. Lucas and W.Th. Ellerman (1978). Between 2007 and 2012, the former Babylon complex was adapted to contemporary requirements and expanded from 44,500 m² to a staggering 145,000 m². An office block and 100-metre-high residential tower were added on the north-west side of the building, while a 140-metre-high residential tower was built on the south-east side. The ground and first floors provide retail space. The upper floors are zoned for offices.[En bild som visar träd, utomhus, himmel, byggnad

Viking Line: Year-End Report January - December 2022

Viking Line Abp                  YEAR-END REPORT              17.02.2023, 9.00 AM    Year-end report for 2022 - a satisfactory year   JANUARY-DECEMBER 2022  (compared to January-December 2021)  · Sales amounted to EUR 494.7 M (EUR 258.2 M).  · Other operating revenue was EUR 24.1 M (EUR 46.8 M).  · Operating income totalled EUR 38.3 M (EUR 32.1 M).  · Net financial items were EUR -10.0 M (EUR -3.8 M).  · Income before taxes totalled EUR 28.3 M (EUR 28.3 M).  · Income after taxes totalled EUR 23.0 M (EUR 24.4 M). · The Board of Directors proposes a dividend

Stille AB: Year-End Report 2022

Stille AB (publ) publishes the year-end report for 2022. ”Solid growth and strong profit deveopment.”, summarizes Niklas Carlén, Stille’s interim CEO.Revenues increased in the fourth quarter by four percent to 61.8 (59.6) and EBIT increased by 60 percent to 8.8 MSEK (5.5). Profitability was positively affected by currency effects. For the full year 2022, sales grew by 76 percent, out of which 16 percent in organic growth. Operating profit increased to 32.4 MSEK (20.1). In the fourth quarter, business unit Surgical Table sales declined by four percent following significant component

SaltX Technology Holding AB Year-end report 2022

SaltX Technology is a Swedish Greentech company that develops and markets sustainable technology that benefits customers, the climate, and society. The company today issues its Year-end report for 2022.“SaltX has entered two significant partnerships with Celsa Armeringsstål in Norway and SSAB. The goal is to supply all their production facilities in the Nordics with climate-neutral lime. The partnerships begin with pre-studies to build new production facilities based on our furnace technology - EAC (Electric Arc Calciner)."  - Carl-Johan Linér, CEO SaltX  Presentation of the Year-end

United Bankers Plc’s Financial Statements Bulletin 2022: Record profit supported by real asset funds

United Bankers Plc 17 February 2023 at 9:00 EET United Bankers Plc’s Financial Statements Bulletin 2022: Record profit supported by real asset funds This stock exchange release is a summary of the United Bankers’ Financial Statements Bulletin 1 January – 31 December 2022. The complete Financial Statements Bulletin with tables is attached to this release and is also available on the company’s website at www.unitedbankers.fi. The figures in this release are unaudited.   January-December 2022 in brief · The Group’s revenue (income from operations) in the financial period

Terveystalo's Annual Report 2022 published

Terveystalo Plc Annual Financial Report 17 February 2023 at 09:00 am EET Terveystalo Plc has today published its Annual Report for the year 2022. The Annual Report 2022 consists of four parts: · Year 2022 presents the strategic development and key events that took place during the year. · Sustainability describes Terveystalo’s sustainability efforts and their results. The Sustainability -section for 2022 is prepared with reference to the GRI Standards. · Corporate Governance includes the Corporate Governance Statement, Remuneration Policy, and Remuneration Report. ·

Metso Outotec’s Financial Statements Review January 1 – December 31, 2022

Metso Outotec Corporation’s stock exchange release on February 17, 2023, at 09:00 a.m. EETFigures in brackets refer to the corresponding period in 2021, unless otherwise stated. Segment information for 2021 has been restated to reflect the segment structure changes that were announced in January 2022. Fourth-quarter 2022 in brief · Strong market activity across all businesses · Orders received increased 21% and totaled EUR 1,590 million (EUR 1,310 million) · Sales grew 12% to EUR 1,434 million (EUR 1,278 million)   · Adjusted EBITA increased 30% to EUR 212 million, or 14.

Exel Composites continues the long-term incentive program for top management

EXEL COMPOSITES PLC      STOCK EXCHANGE RELEASE      17 FEBRUARY 2023 at 08:50 EETThe Board of Directors of Exel Composites Plc has decided on the continuation of the share-based long-term incentive program for the top management of Exel Composites. The 2023 performance-based plan is part of the share-based long-term incentive program published on 4 May 2017, which objectives are to align the interests of the management with those of the company’s shareholders and, thus, to promote shareholder value creation in the long term, to commit the management to achieving the strategic targets of

Paul Sohlberg to start as Exel Composites' President and CEO on 20 March 2023

EXEL COMPOSITES PLC      STOCK EXCHANGE RELEASE      17 FEBRUARY at 08:45 EETPaul Sohlberg’s starting date as President and CEO of Exel Composites Plc has been specified. He will start in the position on 20 March 2023. On 25 October 2022, Exel Composites announced Paul Sohlberg’s appointment and that he will assume his position latest on 1 May 2023.   As earlier announced, Exel Composites’ Board Member Jouni Heinonen will continue as Interim President and CEO of Exel Composites until Paul Sohlberg assumes his new position, assuring a smooth transition.     For further

Year-end report January–December 2022

Fourth quarter · Revenue amounted to €397.7m (€376.3m), an increase of 5.7% with an organic reduction of 2.5%. · Operating profit (EBIT) was €8.7m (€41.6m), representing an operating margin of 2.2% (11.1%). · Net profit amounted to €2.2m (€28.4m), which represents a margin of 0.5% (7.6%). · EBITDA was €53.0m (€75.1m), a decrease by 29.6%. EBITDA margin was 13.3% (20.0%). · EBITDAaL amounted to €29.9m (€56.9m), corresponding to an EBITDAaL margin of 7.5% (15.1%). · Net cash flow from operating activities was €41.2m (€53.9m). · Basic/diluted earnings per share were €0.

ADDvise signs Letter of Intent to acquire Diabetic Supplies Inc.

ADDvise Group has signed a Letter of Intent with the shareholder of Diabetic Supplies Inc. (”Diabetic Supplies” or the “Company”) regarding an acquisition of all shares in Diabetic Supplies. Diabetic Supplies is based in Columbus, Ohio, USA and is a distributor of medical devices for diabetic patients. The Company distributes, among other things, continuous glucose monitors and insulin pumps. Over Diabetic Supplies twenty years of operations, the Company has established a strong customer portfolio of American insurance companies. The Company provides diabetes patients with the necessary

Moving forward

FOURTH QUARTER 2022 · Revenue increased 48% to SEK 705m (475) · Operating profit increased 47% to SEK -13m (-25) · Adjusted1 operating profit increased 47% to SEK -13m (-25) · Adjusted1 operating margin increased to -1.9% (-5.4) · The result for the period decreased by 123% to SEK -21m (88) · Basic earnings per share2 amounted to SEK -1.42 (6.06) · Cash flows from operating activities amounted to SEK -48m (-81)       JANUARY - DECEMBER 2022 · Revenue increased by 31% to SEK 1,973m (1,511) · Operating profit increased 321% to SEK 247m (-112) ·

Observe Medical ASA: Fourth quarter 2022 results

Observe Medical ASA: Fourth quarter 2022 results Oslo, 17 February 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases its results for the fourth quarter of  2022. "The year 2022 has been a transformational year for Observe Medical. Building on the growth initiatives seen earlier in the year, we signed two exclusivity agreements in the fourth quarter to acquire a market leading product portfolio of urine measurement systems and a medical production facility in Italy. It has been an exciting final quarter and looking ahead, our roadmap is clear - we are

Aker ASA: Fourth Quarter and Preliminary Annual Results 2022 – Net Asset Value of NOK 66.9 billion – cash dividend of NOK 15.0 per share proposed

The Net Asset Value ("NAV") of Aker ASA and holding companies ("Aker") ended the fourth quarter at NOK 66.9 billion, compared to NOK 69.0 billion at the end of the third quarter. Adjusted for dividend, this represented a decrease of 1.5 percent. For the full year, the NAV decreased 1 percent, adjusted for dividend, from NOK 69.8 billion at year-end 2021. The Board proposes to pay a cash dividend of NOK 15.0 per share for 2022 and will propose for an authorization to pay an additional cash dividend in the second half of 2023.The per-share NAV amounted to NOK 900, as per 31 December 2022,

Axactor ASA: Fourth quarter financial results

(Oslo, 17 February 2023) Axactor ASA (Axactor, OSE: ACR) announce fourth quarter financial results. Key figures Q4 and full year 2022 for continuing operations (Change from Q4 and full year 2021 in brackets)* Gross revenue- Q4: EUR 89m (up 13%)- FY2022: EUR 337m (up 10%) Total income- Q4: EUR 63m (up 351%)- FY2022: EUR 240m (up 51%) EBITDA- Q4: EUR 31m (up from EUR -17m)- FY2022: EUR 119m (up 194%) Cash EBITDA- Q4: EUR 58m (up 18%)- FY2022: EUR 218m (up 14%) Return on equity- Q4: 10% (up 42pp)- FY2022: 10% (up 16pp) NPL investments- Q4: EUR 93m (up

Multiconsult awarded contract with Equinor

Multiconsult (Oslo: Multi) has been awarded a contract from Equinor and the Snøhvit partners to deliver detail engineering of the grid connection for the Snøhvit Future project.The contract value is estimated to approximately NOK 38 million, and Multiconsult’s delivery is scheduled to be completed during 2023. The contract includes an option for further management assistance and site support during the construction period.  The Snøhvit Future project consists of land compression and electrification of the Hammerfest LNG facilities. The electrification of Equinor’s facility at Melkøya

Bioretec Ltd’s financial statements bulletin 2022: We are delighted about the sales growth and look forward to future approvals

Bioretec Ltd  Company announcement 17 February 2023 at 8:00 a.m.This is a summary of Bioretec Ltd’s financial statements bulletin for January–December 2022. The complete financial statements bulletin with tables is attached to this release as a pdf file and available on the company’s web pages at https://bioretec.com/investors/investors-in-english/releases. July–December 2022 in brief · Net sales increased by 59% and amounted to EUR 1,520 thousand (7-12/2021: EUR 956 thousand). · Sales margin was EUR 1,121 (598) thousand or 73.8% (62.6%) of net sales, with year-on-year growth of

INTERIM REPORT, JANUARY – DECEMBER 2022

The figures refer to the Group unless otherwise stated. Figures in parentheses refer to the corresponding period of 2021 unless otherwise stated. FOURTH QUARTER 2022 · Revenues increased to SEK 17.1 M (11.9). · Earnings before depreciation and amortization (EBITDA) amounted to SEK -4.8 M (-6.7). · Earnings before interest and taxes (EBIT) amounted to SEK -10.0 M (-12.4). · Bringing loss for the period to SEK -10.4 M (-13.4). · Loss per share -0.31 (-0.79). SIGNIFICANT EVENTS IN THE FOURTH QUARTER · Sileon signed its first BNPL SaaS agreement with Hungarian

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top